Inxmed (shanghai) Co., Ltd.
Clinical trials sponsored by Inxmed (shanghai) Co., Ltd., explained in plain language.
-
Trial tests new drug duo against Tough-to-Treat cancer mutation
Disease control Recruiting nowThis study is testing a new combination of two drugs, IN10018 and RNK08954, for people with advanced solid tumors that have a specific genetic change called KRASG12D. The main goals are to find a safe and effective dose and to see if the treatment can shrink tumors. The study is …
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Breakthrough combo therapy trial offers new hope for Tough-to-Treat lung cancer
Disease control Recruiting nowThis study is testing whether a new two-drug combination (IN10018 plus D-1553) works better than the current standard first treatment for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The trial will involve about 400 adults w…
Phase: PHASE3 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC